IRVINE, Calif., June 14, 2011 /PRNewswire/ --ChromaDex Corp. (OTCBB: CDXC) today announced that it has released the company’s new investor presentation. The presentation can be found at investors.chromadex.com. Company President William F. Spengler will be presenting this business outlook at the Accredited Members investment conference today at the Hyatt Regency Denver Tech Center in Denver, Colorado. For further details please visit their website at http://www.accreditedmembers.com/conference.
Comprehensive Strategic Plan for Growth
By executing the plan, ChromaDex will drive growth and increase shareholder value through four key initiatives:
- Continuing to grow our legacy business in fine phytochemicals and contract services,
- Fully commercializing pTeroPure® across multiple market channels such as dietary supplement, food & beverage, beauty & personal care, and pharmaceutical markets,
- Aggressively growing revenues associated with BluScience, the Company’s new retail brand which it announced yesterday, as being initially launched at GNC,
- Through science-based leadership in the natural products market, the Company will continue developing its existing product pipeline and acquire new proprietary products with intellectual property.
“Bill Spengler will be presenting our strategic plan for growth today,” said Frank Jaksch Jr., Co-Founder and CEO of ChromaDex, Inc. “This presentation will highlight that the company is at an inflection point in its history and is about to embark on a period of accelerated growth.”
“This plan indicates that the company represents an opportunity for creating value for our shareholders,” remarked Tom Varvaro, CFO of ChromaDex, Inc. “We are pleased to be able to communicate the company’s direction.”
About ChromaDex
ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.
ChromaDex Forward-Looking Statements
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com
ChromaDex Media Inquiries:
Carolyn Hawley
Canale Communications
619-849-5375
carolyn@canalecomm.com
SOURCE ChromaDex Corp.
